NeoPharm (A092730) Stock Overview
Engages in the manufacturing and sale of skin care products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for A092730 from our risk checks.
A092730 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NeoPharm CO., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,020.00 |
| 52 Week High | ₩22,650.00 |
| 52 Week Low | ₩13,820.00 |
| Beta | 0.56 |
| 1 Month Change | -12.63% |
| 3 Month Change | -3.90% |
| 1 Year Change | 11.75% |
| 3 Year Change | 69.35% |
| 5 Year Change | -7.25% |
| Change since IPO | 309.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| A092730 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -1.0% | -0.01% | -7.9% |
| 1Y | 11.8% | 10.7% | 164.6% |
Return vs Industry: A092730 exceeded the KR Personal Products industry which returned 10.7% over the past year.
Return vs Market: A092730 underperformed the KR Market which returned 164.6% over the past year.
Price Volatility
| A092730 volatility | |
|---|---|
| A092730 Average Weekly Movement | 5.8% |
| Personal Products Industry Average Movement | 8.0% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in KR Market | 15.9% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A092730 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A092730's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 178 | Yangsu Kim | www.neopharm.co.kr |
NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand.
NeoPharm CO., LTD. Fundamentals Summary
| A092730 fundamental statistics | |
|---|---|
| Market cap | ₩266.21b |
| Earnings (TTM) | ₩27.82b |
| Revenue (TTM) | ₩132.18b |
Is A092730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A092730 income statement (TTM) | |
|---|---|
| Revenue | ₩132.18b |
| Cost of Revenue | ₩45.79b |
| Gross Profit | ₩86.40b |
| Other Expenses | ₩58.58b |
| Earnings | ₩27.82b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.78k |
| Gross Margin | 65.36% |
| Net Profit Margin | 21.05% |
| Debt/Equity Ratio | 0% |
How did A092730 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 19:42 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeoPharm CO., LTD. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiseon An | DAOL Investment & Securities Co., Ltd. |
| Byung-Ki Kim | Hanwha Investment & Securities Co., Ltd. |
| Seung Wook Lee | Hanwha Investment & Securities Co., Ltd. |